Please assess the completion status of the following clinical trial:

Trial Title: A Non-Invasive Neuromodulation Device for Prevention of Episodic Migraine Headache

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* diagnosed with episodic migraine at least 6 months before study~* at least 3 consecutive months of stable migraine headaches before study~* at least 4-14 headache days per month, of which 4-14 may be migraines~* must not have failed on more than 2 classes of migraine preventatives~Exclusion Criteria:~* previous use of the experimental device~* pregnant~* using more than 1 concurrent migraine preventive~* history of cardiovascular disease~* work night shifts~* diagnosed with vestibular migraine~* menstrual migraines exclusively~* diagnosed with post-traumatic migraine~* have a history of unstable mood or anxiety disorder~* use a hearing aid~* have a cochlear implant~* have chronic tinnitus~* have temporomandibular joint disease~* diagnosed with traumatic brain injury~* diagnosed with neurological disease other than headaches~* diagnosed vestibular and/or balance dysfunction~* history of abusing alcohol or other drugs~* are experiencing medication overuse headaches~* have had eye surgery in the previous 3 months~* have had ear surgery in the previous 6 months~* have active ear infections or a perforated tympanic membrane~* have participated in another clinical trial in the last 30 days~* are currently participating in another clinical trial~* using Botulinum toxin-based treatments for migraines or cosmetic reasons~* taking anti-emetics more than 2 times per week (consistently)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- active (Type: ACTIVE_COMPARATOR): active neuromodulation
- placebo (Type: PLACEBO_COMPARATOR): placebo neuromodulation

Based on this trial design, predict the completion outcome and termination type (if applicable).